Detalhe da pesquisa
1.
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration.
Mol Immunol
; 165: 29-41, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142486
2.
Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5.
PLoS One
; 18(4): e0284502, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37079521